|
시장보고서
상품코드
1562251
북미의 트랜스페션 시약 및 장비 시장 예측(-2030년) : 지역별 분석 - 제품, 방법, 용도, 최종사용자별North America Transfection Reagents and Equipment Market Forecast to 2030 - Regional Analysis - by Product, Method, Application, and End User |
||||||
북미 트랜스페션 시약 및 장비 시장은 2022년 5억 4,057만 달러로 평가되며, 2030년에는 9억 9,553만 달러에 달할 것으로 예상되며, 2022년부터 2030년까지 7.9%의 CAGR을 기록할 것으로 추정됩니다.
북미 트랜스페션 시약 및 장비 시장을 뒷받침하는 기업들의 전략적인 노력
북미 트랜스페션 시약 및 장비 시장에서 사업을 전개하는 기업들은 공동연구, 사업 확장, 계약, 제휴, 신제품 출시 등 전략적 개척에 주력하고 있으며, 이는 매출 향상, 지리적 범위 확대, 기존 고객보다 더 많은 고객에 대응할 수 있는 역량 강화에 기여하고 있습니다. 또한, 이러한 신흥국 시장 개척은 시장에 새로운 트렌드를 불러일으키는 요인으로 작용하고 있습니다. 북미 트랜스페션 시약 및 장비 시장에서 주목할 만한 몇 가지 동향은 다음과 같습니다.
2023년 4월, Thermo Fisher Scientific은 Invitrogen Neon NxT 일렉트로포레이션 시스템을 출시했습니다. Neon NxT 전극은 최소한의 표면적을 제공하고, 보다 균일한 전기장을 생성하기 위해 최적으로 배치되어, 가장 까다로운 세포 유형도 쉽게 이식할 수 있으며, 이식하는 동안 적절한 생리적 조건을 유지하여 더 많은 세포에서 원하는 형질전환이 이루어질 수 있도록 한다, 이를 통해 더 많은 세포에서 원하는 변형이 이루어질 수 있도록 하여 공정 중에 손실되는 세포 수를 줄입니다. 새로운 시스템은 또한 개선된 피드백 루프와 향상된 인체공학적 사용 편의성을 특징으로 합니다. 2021년 8월, 밀스바이오는 유전자 치료제 개발용 바이러스 벡터 생산을 지원하는 트랜스펙션 시약과 인핸서를 제공하는 TransIT TransIT VirusGEN GMP 제품군을 출시하여 재조합 AAV 및 LV 벡터의 생산 효율을 높이기 위해 부유 및 부착된 HEK 293 세포로 이동 백신 DNA의 전달을 강화하기 위해 개발되었습니다. 2020년 7월, Polyplus-transfection SA는 세포 및 유전자 치료용 렌티바이러스 및 아데노부수체 바이러스(AAV) 생산의 전임상, 임상 및 상업적 공정 개발을 지원하기 위해 고안된 PEIpro 트랜스펙션 시약의 PEIpro 제품 포트폴리오에 대한 첫 번째 GMP 준수 잔류시험을 시작했습니다. 또한, 폴리플러스 트랜스펙션은 후기 및 상업화 단계의 세포 및 유전자 치료용 PEIpro-GMP 제품의 이중 소싱을 시작했습니다. 이와 같이, 폴리플러스 트랜스페션은 다양한 건강 문제를 타깃으로 한 혁신적 제품 개발을 통한 신제품 및 개선품 창출, 시장 경쟁력을 유지하기 위한 신규 사업 시작 등 협업과 파트너십을 통해 트랜스페션 시약 및 시스템과 같은 제품을 도입하고 있다, 트랜스펙션 시약 및 장비의 새로운 플랫폼 개발을 가속화할 수 있습니다.
북미 트랜스펙션 시약 및 장비 시장 개요
세포-유전자 치료제(CGT)는 치료가 필요한 심각한 희귀질환을 앓고 있는 환자들을 치료하기 위해 처방되며, CGT의 제조는 매우 복잡한 과정으로 인프라 및 전문 지식의 부족이 큰 제약요인으로 작용하고 있습니다. CGT의 제조 공정에는 자가 세포를 추출하는 '아펠레시스', 전문 연구소에 보내는 '아펠레시스', 환자에게 투여하기 위해 클리닉으로 보내는 '아펠레시스', 엄격한 품질 관리 하에 이루어지는 '아펠레시스', 그리고 환자에게 투여하는 '아펠레시스' 등 다양한 물류 관련 문제가 있습니다. 이루어져야 합니다. 미국 식품의약국(FDA)이 지금까지 승인한 CGT 의약품은 7종에 불과하며, 실험적인 치료법으로 1,200여 종에 달하는 신제품 파이프라인이 있습니다. 그 중 절반은 임상 2상 단계에 있습니다. 이러한 전망에 따라 Chemical & Engineering News Report 2023에 따르면, 세포 치료제와 유전자 치료제의 연간 매출은 각각 15%와 -30% 성장할 것으로 추정됩니다.
많은 제조업체들이 CGT 제품의 생산 및 상업화 관련 장벽을 극복하기 위해 Labcorp, Lonza, Catalent와 같은 CDMO(위탁개발 및 제조대행업체)에 접근하고 있습니다. 론자는 세포 및 유전자 치료제 생산능력을 강화하기 위해 약 920만 달러를 투자했으며, 이러한 CDMO의 노력은 미국 내 세포 및 유전자 치료제 시장의 성장에 기여하고 있습니다.
또한, 2022년 2월 프랑수아 필립 샴페인(Francois Philippe Champagne) 혁신-과학 - 산업부 장관은 캐나다혁신재단(CFI)을 통해 연구팀이 적절한 연구실과 인프라를 확보하고 세계적 수준의 연구를 수행할 수 있는 기술 부문에 대한 접근성을 확보하기 위해 캐나다 혁신재단(CFI)을 통해 캐나다 정부에 4,500만 달러의 자금을 지원한다고 발표했습니다. 캐나다 보건연구원(CIHR)은 퀘벡 신약개발 컨소시엄(CQDM)과 협력하여 신약개발과 의약품 개발을 가속화하기 위해 맞춤형 의료에 대한 새로운 공동 보조금 프로그램을 시행한다고 발표했습니다.
북미 트랜스페션 시약 및 장비 시장 매출 및 2030년까지의 예측(금액)
북미 트랜스펙션 시약 및 장비 시장 세분화
북미 트랜스페션 시약 및 장비 시장은 제품, 방법, 용도, 최종사용자, 국가별로 구분됩니다.
제품별로 보면 북미의 트랜스페션 시약 및 장비 시장은 시약과 장비로 나뉘며, 2022년에는 시약 부문이 큰 비중을 차지했습니다.
기법별로 북미의 트랜스페션 시약 및 장비 시장은 바이러스 방식, 비바이러스 방식, 하이브리드 방식으로 구분되며, 2022년에는 비바이러스 방식이 가장 큰 점유율을 차지했습니다. 바이러스 방식은 레트로바이러스, 아데노바이러스, 아데노 관련 바이러스, 헤르페스 바이러스로 분류됩니다. 비바이러스성 부문은 물리적/기계적 방법과 화학적 방법으로 나뉩니다. 또한, 물리적/기계적 방법은 일렉트로포레이션법, 마이크로 인젝션법, 바이오리스틱법, 레이저법, 마그네토펙션법, 소노포레이션법으로 세분화됩니다. 또한, 화학적 방법은 리포좀 기반/고지질과 비리포좀/고지질 기반으로 세분화됩니다.
용도별로 북미 트랜스페션 시약 및 기기 시장은 생물의학 연구, 단백질 생산, 치료 전달로 구분됩니다. 2022년에는 바이오메디컬 연구 부문이 가장 큰 점유율을 차지했습니다.
최종사용자별로는 북미의 트랜스페션 시약 및 기기 시장은 학술 및 연구 기관과 제약 및 생명공학 기업으로 양분되며, 2022년에는 학술 및 연구 기관 부문이 더 큰 점유율을 차지했습니다.
국가별로 보면 북미의 트랜스페션 시약 및 장비 시장은 미국, 캐나다, 멕시코로 분류되며, 2022년 북미 트랜스페션 시약 및 장비 시장은 미국이 지배적이었습니다.
Thermo Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Virus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, MaxCyte Inc, Polyplus-Transfection SA, MaxCyte Inc, Polyplus-Transfection SA는 북미 트랜스페션 시약 및 장비 시장에서 활동하는 주요 기업 중 일부입니다.
목차
제1장 소개
제2장 주요 요약
- 주요 인사이트
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 북미 트랜스펙션 시약 및 장비 시장 - 주요 시장 역학
- 북미의 트랜스펙션 시약 및 장비 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 세포 치료와 유전자 치료의 인기 상승
- 암의 경제적 부담 증대
- 시장 성장 억제요인
- 기기 및 소모품의 고비용
- 시장 기회
- 소규모 프로세스에서 대규모 프로세스로의 확대
- 향후 동향
- 기업의 전략적 대처
- 성장 촉진요인과 억제요인의 영향
제5장 트랜스펙션 시약 및 장비 시장 : 북미 시장 분석
- 북미의 트랜스펙션 시약 및 장비 시장 매출, 2022-2030년
- 북미의 트랜스펙션 시약 및 장비 시장 예측 분석
제6장 북미의 트랜스펙션 시약 및 장비 시장 분석 : 제품별
- 시약
- 장비
제7장 북미의 트랜스펙션 시약 및 장비 시장 분석 : 모달리티별
- 바이러스
- 비바이러스
- 하이브리드
제8장 북미의 트랜스펙션 시약 및 장비 시장 분석 : 용도별
- 바이오메디컬 연구
- 단백질 생산
- 치료 딜리버리
제9장 북미의 트랜스펙션 시약 및 장비 시장 분석 : 최종사용자별
- 학술·연구기관
- 제약·바이오테크놀러지 기업
제10장 북미의 트랜스펙션 시약 및 장비 시장 : 국가별 분석
- 북미
- 미국
- 캐나다
- 멕시코
제11장 트랜스펙션 시약 및 장비 시장 : 업계 상황
- 트랜스펙션 시약 및 장비 시장의 성장 전략, 2020-2023년
- 무기적 성장 전략
- 유기적 성장 전략
제12장 기업 개요
- Thermo Fisher Scientific Inc
- Promega Corp
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories Inc
- Mirus Bio LLC
- QIAGEN NV
- Merck KGaA
- Lonza Group AG
- MaxCyte Inc
- Polyplus-Transfection SA
제13장 부록
ksm 24.10.10The North America transfection reagents and equipment market was valued at US$ 540.57 million in 2022 and is expected to reach US$ 995.53 million by 2030; it is estimated to register at a CAGR of 7.9% from 2022 to 2030.
Strategic Initiatives by Companies Fuel North America Transfection Reagents and Equipment Market
Companies operating in the North America transfection reagents and equipment market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic scope, and enhance their capacities to cater to a larger than existing customer base. These developments also contribute to the introduction of new trends to the market to a certain extent. A few of the noteworthy developments in the North America transfection reagents and equipment market are mentioned below.
In April 2023, Thermo Fisher Scientific launched the Invitrogen Neon NxT Electroporation System that facilitates transfection, even with the most challenging cell types, enabling high efficiency, cell recovery, and reproducibility. Neon NxT electrodes are optimally placed to provide minimal surface area and create a more uniform electric field, and maintain apt physiological conditions during transfection, thereby enabling the desired modification to take place in more cells and reducing the number of cells lost during the process. The new system also features an improved feedback loop and ergonomic enhancements for ease of use. In August 2021, Mirus Bio launched the TransIT VirusGEN GMP Product Line, which provides transfection reagents and enhancers to support the manufacturing of viral vectors for the development of gene therapies. The TransIT VirusGEN GMP transfection reagent was developed to enhance the delivery of transfer vaccine DNA to suspension and adherent HEK 293 cells to make the production of recombinant AAV and LV vectors more efficient. In July 2020, Polyplus-transfection SA launched the first GMP-compliant residual test for its PEIpro product portfolio of transfection reagents designed to support the development of the preclinical, clinical, and commercial process of lentivirus and adeno-associated virus (AAV) production for cell and gene therapies. In addition, Polyplus-transfection also launched dual sourcing for its PEIpro-GMP product for late-stage and commercialization cell and gene therapies. Thus, the introduction of products such as transfection reagents and systems; the development of innovative products targeting various health issues to create new or improved products; and the initiation of new businesses to remain competitive in the market, all, through collaborations and partnerships can help speed up the development of new platforms for transfection reagents and equipment.
North America Transfection Reagents and Equipment Market Overview
Cell and gene therapies (CGTs) are prescribed to treat patients suffering from serious and rare diseases with unaddressed therapeutic needs. Manufacturing CGTs is a highly complex process, with the insufficiency of infrastructure and expertise being a major limiting factor. Logistics-related challenges associated with intermediates and the final product also limit the CGT manufacturing capacity of companies. The CGT manufacturing process involves the extraction of autologous cells through "apheresis," dispatching them to specialized laboratories and sending them back to clinics for administration into patients, all of which must be performed with strict quality control. The US Food and Drug Administration (FDA) has approved only 7 CGT drugs so far, and the pipeline of new products has reached ~1,200 experimental therapies. Half of these are in Phase 2 clinical trials. With these prospects, annual sales of cell therapies and gene therapies are estimated to grow by 15% and ~30%, respectively, as stated in the Chemical & Engineering News Report 2023.
Many manufacturers approach contract development manufacturing organizations (CDMOs) such as Labcorp, Lonza, and Catalent to overcome the barriers associated with the production and commercialization of their CGT products. Lonza has invested ~US$ 9.2 million to strengthen its cell and gene therapy manufacturing capabilities. Such initiatives by CDMOs are contributing to the growth of the transfection reagents and equipment market in the US.
Furthermore, in February 2022, Francois-Philippe Champagne, the minister of Innovation, Science and Industry, announced the funding of US$ 45 million to the Government of Canada through the Canada Foundation for Innovation (CFI) to ensure that research teams have appropriate labs and infrastructure, and access to technology departments for carrying about world-class research. The Canadian Institutes of Health Research (CIHR) announced a partnership with the Quebec Consortium for Drug Discovery (CQDM) for a new collaborative funding program on personalized medicine to accelerate drug discovery and drug development.
North America Transfection Reagents and Equipment Market Revenue and Forecast to 2030 (US$ Million)
North America Transfection Reagents and Equipment Market Segmentation
The North America transfection reagents and equipment market is segmented based on product, method, application, end user, and country.
Based on product, the North America transfection reagents and equipment market is bifurcated into reagents and instruments. The reagents segment held a larger share in 2022.
In terms of method, the North America transfection reagents and equipment market is segmented into viral methods, non-viral methods, and hybrid methods. The non-viral methods segment held the largest share in 2022. The viral segment is sub categorized into retrovirus, adenovirus, adeno associated virus, and herpes virus. The non-viral segment is bifurcated into physical/mechanical method and chemical method. Further, the physical/mechanical method segment is sub categorized into electroporation, microinjection, biolistic method, laser method, magnetofection, and sonoporation. Also, the chemical method segment is sub categorized into liposomal based/high lipid and non-liposomal/high lipid based.
By application, the North America transfection reagents and equipment market is segmented into biomedical research, protein production, and therapeutic delivery. The biomedical research segment held the largest share in 2022.
Based on end user, the North America transfection reagents and equipment market is bifurcated into academics & research institutes and pharmaceutical & biotechnology companies. The academics & research institutes segment held a larger share in 2022.
Based on country, the North America transfection reagents and equipment market is categorized into the US, Canada, and Mexico. The US dominated the North America transfection reagents and equipment market in 2022.
Thermo Fisher Scientific Inc, Promega Corp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Mirus Bio LLC, QIAGEN NV, Merck KGaA, Lonza Group AG, MaxCyte Inc, and Polyplus-Transfection SA are some of the leading companies operating in the North America transfection reagents and equipment market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Transfection Reagents and Equipment Market - Key Market Dynamics
- 4.1 North America Transfection Reagents and Equipment Market - Key Market Dynamics
- 4.2 Market Drivers
- 4.2.1 Increasing Popularity of Cell and Gene Therapy
- 4.2.2 Growing Economic Burden of Cancer
- 4.3 Market Restraints
- 4.3.1 High Cost of Instruments and Consumables
- 4.4 Market Opportunities
- 4.4.1 Ramping Up Small-Scale Processes to Large-Scale Processes
- 4.5 Future Trends
- 4.5.1 Strategic Initiatives by Companies
- 4.6 Impact of Drivers and Restraints:
5. Transfection Reagents and Equipment Market - North America Market Analysis
- 5.1 North America Transfection Reagents and Equipment Market Revenue (US$ Million), 2022-2030
- 5.2 North America Transfection Reagents and Equipment Market Forecast Analysis
6. North America Transfection Reagents and Equipment Market Analysis - by Product
- 6.1 Reagents
- 6.1.1 Overview
- 6.1.2 Reagents: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.2 Equipment
- 6.2.1 Overview
- 6.2.2 Equipment: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Transfection Reagents and Equipment Market Analysis - by Modality
- 7.1 Viral
- 7.1.1 Overview
- 7.1.2 Viral: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.1.2.1 Retrovirus: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.1.2.2 Adenovirus: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.1.2.3 Adeno-Associated Virus: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.1.2.4 Herpes Virus: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2 Non-Viral
- 7.2.1 Overview
- 7.2.2 Non-Viral: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1 Physical/Mechanical Method: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.1 Electroporation: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.2 Microinjection: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.3 Biolistic Method: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.4 Laser Method: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.5 Magnetofection: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1.6 Sonoporation: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.2 Chemical Method: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.2.1 Liposomal Based/High Lipid: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.2.2 Non-Liposomal Based/High Lipid: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2.2.1 Physical/Mechanical Method: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3 Hybrid
- 7.3.1 Overview
- 7.3.2 Hybrid: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Transfection Reagents and Equipment Market Analysis - by Application
- 8.1 Biomedical Research
- 8.1.1 Overview
- 8.1.2 Biomedical Research: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 8.2 Protein Production
- 8.2.1 Overview
- 8.2.2 Protein Production: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3 Therapeutic Delivery
- 8.3.1 Overview
- 8.3.2 Therapeutic Delivery: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Transfection Reagents and Equipment Market Analysis - by End Users
- 9.1 Academic and Research Institutes
- 9.1.1 Overview
- 9.1.2 Academic and Research Institutes: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2 Pharmaceutical and Biotechnological Companies
- 9.2.1 Overview
- 9.2.2 Pharmaceutical and Biotechnological Companies: North America Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Transfection Reagents and Equipment Market -Country Analysis
- 10.1 North America: Transfection Reagents and Equipment Market - Revenue and Forecast Analysis - by Country
- 10.1.1 North America: Transfection Reagents and Equipment Market - Revenue and Forecast Analysis - by Country
- 10.1.1.1 United States: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.1.1 United States: Transfection Reagents and Equipment Market Breakdown, by Product
- 10.1.1.1.2 United States: Transfection Reagents and Equipment Market Breakdown, by Modality
- 10.1.1.1.2.1 United States: Transfection Reagents and Equipment Market Breakdown, by Viral
- 10.1.1.1.2.2 United States: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
- 10.1.1.1.2.2.1 United States: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
- 10.1.1.1.2.2.2 United States: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
- 10.1.1.1.3 United States: Transfection Reagents and Equipment Market Breakdown, by Application
- 10.1.1.1.4 United States: Transfection Reagents and Equipment Market Breakdown, by End Users
- 10.1.1.2 Canada: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Canada: Transfection Reagents and Equipment Market Breakdown, by Product
- 10.1.1.2.2 Canada: Transfection Reagents and Equipment Market Breakdown, by Modality
- 10.1.1.2.2.1 Canada: Transfection Reagents and Equipment Market Breakdown, by Viral
- 10.1.1.2.2.2 Canada: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
- 10.1.1.2.2.2.1 Canada: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
- 10.1.1.2.2.2.2 Canada: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
- 10.1.1.2.3 Canada: Transfection Reagents and Equipment Market Breakdown, by Application
- 10.1.1.2.4 Canada: Transfection Reagents and Equipment Market Breakdown, by End Users
- 10.1.1.3 Mexico: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 Mexico: Transfection Reagents and Equipment Market Breakdown, by Product
- 10.1.1.3.2 Mexico: Transfection Reagents and Equipment Market Breakdown, by Modality
- 10.1.1.3.2.1 Mexico: Transfection Reagents and Equipment Market Breakdown, by Viral
- 10.1.1.3.2.2 Mexico: Transfection Reagents and Equipment Market Breakdown, by Non-Viral
- 10.1.1.3.2.2.1 Mexico: Transfection Reagents and Equipment Market Breakdown, by Physical/mechanical Method
- 10.1.1.3.2.2.2 Mexico: Transfection Reagents and Equipment Market Breakdown, by Chemical Method
- 10.1.1.3.3 Mexico: Transfection Reagents and Equipment Market Breakdown, by Application
- 10.1.1.3.4 Mexico: Transfection Reagents and Equipment Market Breakdown, by End Users
- 10.1.1.1 United States: Transfection Reagents and Equipment Market - Revenue and Forecast to 2030 (US$ Million)
- 10.1.1 North America: Transfection Reagents and Equipment Market - Revenue and Forecast Analysis - by Country
11. Transfection Reagents and Equipment Market -Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies in The Transfection Reagents and Equipment Market, 2020-2023
- 11.3 Inorganic Growth Strategies
- 11.3.1 Overview
- 11.4 Organic Growth Strategies
- 11.4.1 Overview
12. Company Profiles
- 12.1 Thermo Fisher Scientific Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Promega Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 F. Hoffmann-La Roche Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Bio-Rad Laboratories Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Mirus Bio LLC
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 QIAGEN NV
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Merck KGaA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Lonza Group AG
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 MaxCyte Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Polyplus-Transfection SA
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
- 13.1 About Us
